4503.T JPX
Astellas Pharma Inc.
1W: -4.8%
1M: -5.3%
3M: +3.2%
YTD: -11.3%
1Y: +39.5%
3Y: +20.8%
5Y: +33.8%
¥2,230.50 ($14.12)
-14.50 (-0.65%)
Weekly Expected Move ±3.3%
¥2097
¥2171
¥2245
¥2319
¥2393
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
#4
of 8
Drug Manufacturers - General
Technical Signal Map
0 Bullish
1 Neutral
7 Bearish
4503.T
$4.0T
Astellas Pharma Inc.
BEARISH
-59
4882.T
$3.1B
Perseus Proteomics Inc.
NEUTRAL
0
4568.T
$5.0T
Daiichi Sankyo Company, Limited
BEARISH
-50
4519.T
$10.2T
Chugai Pharmaceutical Co., Ltd.
BEARISH
-66
4578.T
$6.0T
Otsuka Holdings Co., Ltd.
BEARISH
-69
4536.T
$545B
Santen Pharmaceutical Co., Ltd.
BEARISH
-78
4528.T
$1.1T
Ono Pharmaceutical Co., Ltd.
BEARISH
-84
4552.T
$61B
JCR Pharmaceuticals Co., Ltd.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| 4503.T Astellas Pharma Inc. | $4.0T | 10.9 | 17.4 | 14.8 | 8.1 | 11.9 | 7 | BEARISH | 39.5 |
| 4882.T Perseus Proteomics Inc. | $3.1B | -3.4 | -51.5 | 178.4 | -575.8 | 9.4 | 5 | NEUTRAL | -60.3 |
| 4568.T Daiichi Sankyo Company, Limited | $5.0T | 20.6 | 15.8 | 13.5 | 7.2 | 12.6 | 4 | BEARISH | -23.1 |
| 4519.T Chugai Pharmaceutical Co., Ltd. | $10.2T | 21.3 | 23.5 | 42.1 | 34.1 | 12.3 | 6 | BEARISH | -2.4 |
| 4578.T Otsuka Holdings Co., Ltd. | $6.0T | 14.8 | 13.6 | 11.8 | 16.7 | 9.1 | 8 | BEARISH | 43.8 |
| 4536.T Santen Pharmaceutical Co., Ltd. | $545B | 13.9 | 12.8 | 14.3 | 19.2 | -2.8 | 8 | BEARISH | 12.8 |
| 4528.T Ono Pharmaceutical Co., Ltd. | $1.1T | 14.0 | 8.5 | 10.6 | 0.7 | 5.9 | 7 | BEARISH | 36.1 |
| 4552.T JCR Pharmaceuticals Co., Ltd. | $61B | 75.3 | 4.6 | 0.3 | 4.4 | 21.9 | 5 | BEARISH | -22.4 |
| 4503.T Astellas Pharma Inc. | $4.0T | 10.9 | 17.4 | 14.8 | 8.1 | 11.9 | 7 | BEARISH | 39.5 |
| 4882.T Perseus Proteomics Inc. | $3.1B | -3.4 | -51.5 | 178.4 | -575.8 | 9.4 | 5 | NEUTRAL | -60.3 |
| 4568.T Daiichi Sankyo Company, Limited | $5.0T | 20.6 | 15.8 | 13.5 | 7.2 | 12.6 | 4 | BEARISH | -23.1 |
| 4519.T Chugai Pharmaceutical Co., Ltd. | $10.2T | 21.3 | 23.5 | 42.1 | 34.1 | 12.3 | 6 | BEARISH | -2.4 |
| 4578.T Otsuka Holdings Co., Ltd. | $6.0T | 14.8 | 13.6 | 11.8 | 16.7 | 9.1 | 8 | BEARISH | 43.8 |
| 4536.T Santen Pharmaceutical Co., Ltd. | $545B | 13.9 | 12.8 | 14.3 | 19.2 | -2.8 | 8 | BEARISH | 12.8 |
| 4528.T Ono Pharmaceutical Co., Ltd. | $1.1T | 14.0 | 8.5 | 10.6 | 0.7 | 5.9 | 7 | BEARISH | 36.1 |
| 4552.T JCR Pharmaceuticals Co., Ltd. | $61B | 75.3 | 4.6 | 0.3 | 4.4 | 21.9 | 5 | BEARISH | -22.4 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
4503.T vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F